Table 2 Summary of Adverse Events in Patients With and Without Daily Headache
AE, n (%) | With Daily Headache (n = 138) | Without Daily Headache (n = 504) |
|---|---|---|
≥1 AE | 99 (71.7) | 297 (58.9) |
Serious AE | 20 (14.5) | 44 (8.7) |
Study discontinuation due to AE | 10 (7.2) | 17 (3.4) |
≥1 TRAE | 24 (17.4) | 97 (19.2) |
Individual TRAEs occurring in ≥1% of any subgroup | ||
Neck pain | 5 (3.6) | 23 (4.6) |
Eyelid ptosis | 3 (2.2) | 14 (2.8) |
Musculoskeletal stiffness | 4 (2.9) | 13 (2.6) |
Injection site pain | 3 (2.2) | 11 (2.2) |
Headache | 2 (1.4) | 8 (1.6) |
Muscular weakness | 1 (0.7) | 9 (1.8) |
Facial paresis | 1 (0.7) | 6 (1.2) |
Migraine | 0 (0.0) | 6 (1.2) |
Skin tightness | 1 (0.7) | 5 (1.0) |
Influenza-like illness | 2 (1.4) | 1 (0.2) |
Balance disorder | 2 (1.4) | 0 (0.0) |
Dizziness | 3 (2.2) | 0 (0.0) |